These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32496799)

  • 1. Programmable One-Pot Synthesis of Heparin Pentasaccharide Fondaparinux.
    Dey S; Lo HJ; Wong CH
    Org Lett; 2020 Jun; 22(12):4638-4642. PubMed ID: 32496799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of the heparin-based anticoagulant drug fondaparinux.
    Chang CH; Lico LS; Huang TY; Lin SY; Chang CL; Arco SD; Hung SC
    Angew Chem Int Ed Engl; 2014 Sep; 53(37):9876-9. PubMed ID: 25044485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended Physicochemical Characterization of the Synthetic Anticoagulant Pentasaccharide Fondaparinux Sodium by Quantitative NMR and Single Crystal X-ray Analysis.
    Wildt W; Kooijman H; Funke C; Üstün B; Leika A; Lunenburg M; Kaspersen F; Kellenbach E
    Molecules; 2017 Aug; 22(8):. PubMed ID: 28817073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical use of Fondaparinux: A synthetic heparin pentasaccharide.
    Zhang Y; Zhang M; Tan L; Pan N; Zhang L
    Prog Mol Biol Transl Sci; 2019; 163():41-53. PubMed ID: 31030756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical synthesis and pharmacological properties of heparin pentasaccharide analogues.
    Zhou Z; Zhang L; Wu X; Luo L; Wu J; Xu D; Wu M
    Eur J Med Chem; 2022 Apr; 234():114256. PubMed ID: 35279609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in the development of oral anticoagulants.
    Ralay-Ranaivo B; Borgel D; Couvreur P; Gref R
    Ther Deliv; 2015; 6(6):685-703. PubMed ID: 26149785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formal Synthesis of Anticoagulant Drug Fondaparinux Sodium.
    Dai X; Liu W; Zhou Q; Cheng C; Yang C; Wang S; Zhang M; Tang P; Song H; Zhang D; Qin Y
    J Org Chem; 2016 Jan; 81(1):162-84. PubMed ID: 26650028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total synthesis of anticoagulant pentasaccharide fondaparinux.
    Li T; Ye H; Cao X; Wang J; Liu Y; Zhou L; Liu Q; Wang W; Shen J; Zhao W; Wang P
    ChemMedChem; 2014 May; 9(5):1071-80. PubMed ID: 24729477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Efficient Modular One-Pot Synthesis of Heparin-Based Anticoagulant Idraparinux.
    Dey S; Lo HJ; Wong CH
    J Am Chem Soc; 2019 Jul; 141(26):10309-10314. PubMed ID: 31244187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins.
    Xu Y; Masuko S; Takieddin M; Xu H; Liu R; Jing J; Mousa SA; Linhardt RJ; Liu J
    Science; 2011 Oct; 334(6055):498-501. PubMed ID: 22034431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides.
    Ludwig RJ; Schindewolf M; Alban S; Kaufmann R; Lindhoff-Last E; Boehncke WH
    Thromb Haemost; 2005 Dec; 94(6):1265-9. PubMed ID: 16411404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational design of anticoagulant drugs using oligosaccharide chemistry.
    El Hadri A; Petitou M
    Chimia (Aarau); 2011; 65(1-2):14-7. PubMed ID: 21469438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemokine Oligomers and the Impact of Fondaparinux Binding.
    Szekeres GP; Dyer DP; Miller RL; Pagel K
    J Am Soc Mass Spectrom; 2024 Jul; 35(7):1550-1555. PubMed ID: 38836362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fondaparinux (Arixtra): a new anticoagulant.
    Giangrande PL
    Int J Clin Pract; 2002 Oct; 56(8):615-7. PubMed ID: 12425373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia.
    Schindewolf M; Steindl J; Beyer-Westendorf J; Schellong S; Dohmen PM; Brachmann J; Madlener K; Pötzsch B; Klamroth R; Hankowitz J; Banik N; Eberle S; Müller MM; Kropff S; Lindhoff-Last E
    J Am Coll Cardiol; 2017 Nov; 70(21):2636-2648. PubMed ID: 29169470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemistry and clinical pharmacology of new anticoagulant agents.
    Samama MM; Gerotziafas GT; Elalamy I; Horellou MH; Conard J
    Pathophysiol Haemost Thromb; 2002; 32(5-6):218-24. PubMed ID: 13679646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic heparin and heparan sulfate: probes in defining biological functions.
    Tsai CT; Zulueta MML; Hung SC
    Curr Opin Chem Biol; 2017 Oct; 40():152-159. PubMed ID: 29032302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases.
    Jappe U; Juschka U; Kuner N; Hausen BM; Krohn K
    Contact Dermatitis; 2004 Aug; 51(2):67-72. PubMed ID: 15373846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of Anticoagulant Pentasaccharide Fondaparinux via 3,5-Dimethyl-4-(2'-phenylethynylphenyl)phenyl Glycosides.
    Liu W; Hu Z; Xu P; Yu B
    Org Lett; 2023 Dec; 25(47):8506-8510. PubMed ID: 37983186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and experimental experience with factor Xa inhibitors.
    Viles-Gonzalez JF; Gaztanaga J; Zafar UM; Fuster V; Badimon JJ
    Am J Cardiovasc Drugs; 2004; 4(6):379-84. PubMed ID: 15554723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.